ACE-031 vs LGD-4033
A side-by-side research comparison of ACE-031 and LGD-4033 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | ACE-031 | LGD-4033 |
|---|---|---|
| Full name | ACE-031 (Soluble ActRIIB-Fc Fusion) | Ligandrol (LGD-4033) |
| Category | Muscle Growth | Muscle Growth |
| Status | Investigational | Investigational |
| Mechanism | Decoy receptor sequestering TGF-B ligands (myostatin, activin, GDF-11) in bloodstream, preventing cell-surface ActRIIB binding and removing multiple anabolic brakes. | Selectively binds androgen receptors in muscle and bone, activating anabolic gene transcription while avoiding prostate activity. |
| Molecular weight | ~90,000 Da | 338.25 Da |
| Half-life | 10-14 days | ~24-36 hours |
| Bioavailability | High (SubQ) | ~90% oral |
| Typical dose | 0.3-3 mg/kg | 5-10 mg |
| Frequency | Every 2-4 weeks | Once daily |
| Route | Subcutaneous | Oral |
ACE-031 reported benefits
- Multi-ligand pathway inhibition
- Lean mass increase
- Bone density increase
- Infrequent dosing
- Functional strength improvement
LGD-4033 reported benefits
- Significant lean mass gains
- Bone density improvement
- Oral convenience
- Selective tissue activity
Related comparisons
Research and educational reference only. Not medical advice.